Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Patients with type 2 diabetes who used a smartphone app for cognitive behavioral therapy showed a significant decrease in A1c levels.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
2.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
3.
Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know
4.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
5.
Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.
1.
Leukemia: Understanding the Disease and Its Impact on Patients
2.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
3.
Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge